Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 522

1.

HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma.

Malissen N, Macagno N, Granjeaud S, Granier C, Moutardier V, Gaudy-Marqueste C, Habel N, Mandavit M, Guillot B, Pasero C, Tartour E, Ballotti R, Grob JJ, Olive D.

Oncoimmunology. 2019 Sep 25;8(12):e1665976. doi: 10.1080/2162402X.2019.1665976. eCollection 2019.

2.

[Authors response to the letter on the article: "The place of Androcur® in the treatment of diffuse female pattern hair loss"].

Pham AD, Guillot B, Beylot-Barry M, Chosidow O, Reygagne P, Joly P.

Ann Dermatol Venereol. 2019 Nov 12. pii: S0151-9638(19)30955-X. doi: 10.1016/j.annder.2019.10.016. [Epub ahead of print] French. No abstract available.

PMID:
31732137
3.

[Characteristics of chronic wounds in substance abuse: A retrospective study of 58 patients].

Martin H, Bursztejn AC, Albuisson E, Leguern A, Mahe E, Villemur B, Blaise S, Perceau G, Goujon E, Lok C, Modiano P, Debure C, Guillot B, Maillard H, Say M, Carvalho-Lallement P, Dompmartin A, Journet-Tollhupp J, Schmutz JL, Senet P, Schoeffler A; au nom du groupe d’Angiodermatologie de la SFD.

Ann Dermatol Venereol. 2019 Oct 21. pii: S0151-9638(19)30315-1. doi: 10.1016/j.annder.2019.09.004. [Epub ahead of print] French.

PMID:
31648848
4.

Quality-of-life assessment in French patients with metastatic melanoma in real life.

Kandel M, Dalle S, Bardet A, Allayous C, Mortier L, Dutriaux C, Guillot B, Leccia MT, Dalac S, Legoupil D, Saiag P, Montaudie H, Arnault JP, Brunet-Possenti F, Grob JJ, DeQuatrebarbes J, Beylot-Barry M, Lesimple T, Aubin F, Maubec E, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I.

Cancer. 2019 Oct 22. doi: 10.1002/cncr.32554. [Epub ahead of print]

PMID:
31639198
5.

Primary Cutaneous Gamma-Delta T-cell Lymphoma: Not an Aggressive Disease in All Cases.

Khallaayoune M, Grange F, Condamina M, Szablewski V, Guillot B, Dereure O.

Acta Derm Venereol. 2019 Oct 14. doi: 10.2340/00015555-3340. [Epub ahead of print] No abstract available.

6.

Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.

Herms F, Lambert J, Grob JJ, Haudebourg L, Bagot M, Dalac S, Dutriaux C, Guillot B, Jeudy G, Mateus C, Monestier S, Mortier L, Poulalhon N, Prey S, Robert C, Vabres P, Lebbe C, Meyer N, Basset-Seguin N.

J Clin Oncol. 2019 Oct 14:JCO1800794. doi: 10.1200/JCO.18.00794. [Epub ahead of print]

PMID:
31609670
7.

Intrinsic Rashba coupling due to hydrogen bonding in DNA.

Varela S, Montañes B, López F, Berche B, Guillot B, Mujica V, Medina E.

J Chem Phys. 2019 Sep 28;151(12):125102. doi: 10.1063/1.5121025.

PMID:
31575191
8.

[Rituximab use in mucous membrane pemphigoid].

Bertrand AS, Dereure O, Girard C, Bessis D, Guillot B.

Ann Dermatol Venereol. 2019 Oct;146(10):659-661. doi: 10.1016/j.annder.2019.07.001. Epub 2019 Jul 26. French. No abstract available.

PMID:
31358309
9.

Polarization of Electron Density Databases of Transferable Multipolar Atoms.

Leduc T, Aubert E, Espinosa E, Jelsch C, Iordache C, Guillot B.

J Phys Chem A. 2019 Aug 15;123(32):7156-7170. doi: 10.1021/acs.jpca.9b05051. Epub 2019 Aug 4.

PMID:
31294565
10.

Myasthenia Gravis Induced by Immune Checkpoint Inhibitors.

Becquart O, Lacotte J, Malissart P, Nadal J, Lesage C, Guillot B, Du Thanh A.

J Immunother. 2019 Oct;42(8):309-312. doi: 10.1097/CJI.0000000000000278.

PMID:
31246640
11.

[French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults].

Amatore F, Villani AP, Tauber M, Guillot B, Viguier M; Groupe de recherche sur le psoriasis de la Société française de dermatologie.

Ann Dermatol Venereol. 2019 Jun - Jul;146(6-7):429-439. doi: 10.1016/j.annder.2019.03.005. Epub 2019 Jun 14. French.

PMID:
31208735
12.

The MgCO3-CaCO3-Li2CO3-Na2CO3-K2CO3 melts: Thermodynamics and transport properties by atomistic simulations.

Desmaele E, Sator N, Vuilleumier R, Guillot B.

J Chem Phys. 2019 Jun 7;150(21):214503. doi: 10.1063/1.5099015.

PMID:
31176344
13.

[Reprint of: New guidelines for stage III melanoma (the French Cutaneous Oncology Group)].

Guillot B, Dupuy A, Pracht M, Jeudy G, Hindie E, Desmedt E, Jouary T, Leccia MT.

Bull Cancer. 2019 Jun;106(6):560-573. doi: 10.1016/j.bulcan.2019.04.001. Epub 2019 May 20. French.

PMID:
31122657
14.

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.

Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Dereure O, Lesage FX, Guillot B; French Group of Onco-Dermatology.

J Immunother. 2019 May 15. doi: 10.1097/CJI.0000000000000268. [Epub ahead of print]

PMID:
31107372
15.

[Hydrochlorothiazide use and risk of skin cancers: A systematic review].

Becquart O, Guillot B, Bourrain JL, Duflos C, Du-Thanh A.

Rev Med Interne. 2019 Sep;40(9):617-622. doi: 10.1016/j.revmed.2019.04.008. Epub 2019 May 14. French.

PMID:
31101331
16.

Risk of suicide attempt associated with isotretinoin: a nationwide cohort and nested case-time-control study.

Droitcourt C, Nowak E, Rault C, Happe A, Le Nautout B, Kerbrat S, Balusson F, Poizeau F, Travers D, Sapori JM, Lagarde E, Rey G, Guillot B, Oger E, Dupuy A.

Int J Epidemiol. 2019 Oct 1;48(5):1623-1635. doi: 10.1093/ije/dyz093.

17.

Incidence and Clinical Impact of Anti-TNFα Treatment of Severe Immune Checkpoint Inhibitor-induced Colitis in Advanced Melanoma: The Mecolit Survey.

Lesage C, Longvert C, Prey S, Maanaoui S, Dréno B, Machet L, Zehou O, Kramkimel N, Jeudy G, Skowron F, Aubin F, Visseaux L, Mansard S, Dereure O, Lesage FX, Guillot B; French Group of Onco-Dermatology.

J Immunother. 2019 Jun;42(5):175-179. doi: 10.1097/CJI.0000000000000268.

PMID:
31090656
18.

Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and Survival.

Vallet A, Oriano B, Mortier L, Dalle S, Dutriaux C, Guillot B, Leccia MT, Dalac S, Saiag P, Lacour JP, Legoupil D, De Quatrebarbes J, Brunet-Possenti F, Lesimple T, Arnault JP, Aubin F, Granel-Brocard F, Stoebner PE, Maubec E, Dreno B, Allayous C, Porcher R, Lebbé C; for MelBase.

JAMA Dermatol. 2019 Jun 1;155(6):673-678. doi: 10.1001/jamadermatol.2019.0425.

PMID:
31042256
19.

[The place of Androcur® in the treatment of diffuse female pattern hair loss].

Pham AD, Guillot B, Beylot-Barry M, Chosidow O, Reygagne P, Joly P.

Ann Dermatol Venereol. 2019 Apr;146(4):311-312. doi: 10.1016/j.annder.2019.02.008. Epub 2019 Mar 27. French. No abstract available.

PMID:
30926139
20.

Impact of radiotherapy administered simultaneously with systemic treatment in patients with melanoma brain metastases within MelBase, a French multicentric prospective cohort.

Tétu P, Allayous C, Oriano B, Dalle S, Mortier L, Leccia MT, Guillot B, Dalac S, Dutriaux C, Lacour JP, Saiag P, Brunet-Possenti F, De Quatrebarbes J, Stoebner PE, Legoupil D, Beylot-Barry M, Lesimple T, Aubin F, Dreno B, Mohamed S, Ballon A, Porcher R, Lebbe C.

Eur J Cancer. 2019 May;112:38-46. doi: 10.1016/j.ejca.2019.02.009. Epub 2019 Mar 22.

PMID:
30909072
21.

No evidence for viral transcripts in dermatofibrosarcoma protuberans.

Du-Thanh A, Pérot P, Foulongne V, Dereure O, Guillot B, Eloit M.

Br J Dermatol. 2019 Sep;181(3):634-636. doi: 10.1111/bjd.17878. Epub 2019 Jul 4. No abstract available.

PMID:
30883688
22.

DORI Reveals the Influence of Noncovalent Interactions on Covalent Bonding Patterns in Molecular Crystals Under Pressure.

Meyer B, Barthel S, Mace A, Vannay L, Guillot B, Smit B, Corminboeuf C.

J Phys Chem Lett. 2019 Apr 4;10(7):1482-1488. doi: 10.1021/acs.jpclett.9b00220. Epub 2019 Mar 18.

23.

Atomistic simulations of molten carbonates: Thermodynamic and transport properties of the Li2CO3-Na2CO3-K2CO3 system.

Desmaele E, Sator N, Vuilleumier R, Guillot B.

J Chem Phys. 2019 Mar 7;150(9):094504. doi: 10.1063/1.5082731.

PMID:
30849908
24.

[New guidelines for stage III melanoma (the French Cutaneous Oncology Group)].

Guillot B, Dupuy A, Pracht M, Jeudy G, Hindie E, Desmedt E, Jouary T, Leccia MT.

Ann Dermatol Venereol. 2019 Mar;146(3):204-214. doi: 10.1016/j.annder.2019.01.011. Epub 2019 Mar 2. French.

PMID:
30833037
25.

French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults.

Amatore F, Villani AP, Tauber M, Viguier M, Guillot B; Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie).

J Eur Acad Dermatol Venereol. 2019 Mar;33(3):464-483. doi: 10.1111/jdv.15340. Epub 2019 Feb 22.

26.

Assessment of quality of life using Skindex-16 in patients with advanced basal cell carcinoma treated with vismodegib in the STEVIE study.

Hansson J, Bartley K, Karagiannis T, Grob JJ, Kunstfeld R, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Fife K, Ernst DS, Yim YM, Dimier N, Fittipaldo A, Basset-Séguin N, Hauschild A.

Eur J Dermatol. 2018 Dec 1;28(6):775-783. doi: 10.1684/ejd.2018.3448.

PMID:
30698147
27.

[Use of the autologous dorsal dermis in reconstruction of the posterior palpebral lamella in blepharopoiesis].

Azoulay L, Prudhomme A, Gleizal A, Guillot B, Chaput B, Herlin C.

Ann Chir Plast Esthet. 2019 Feb;64(1):44-53. doi: 10.1016/j.anplas.2018.07.006. Epub 2018 Nov 30. French.

PMID:
30509685
28.

Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort.

Kandel M, Allayous C, Dalle S, Mortier L, Dalac S, Dutriaux C, Leccia MT, Guillot B, Saiag P, Lacour JP, Legoupil D, Lesimple T, Aubin F, Beylot-Barry M, Brunet-Possenti F, Arnault JP, Granel-Brocard F, Stoebner PE, Dupuy A, Maubec E, Grob JJ, Dreno B, Rotolo F, Ballon A, Michiels S, Lebbe C, Borget I.

Eur J Cancer. 2018 Dec;105:33-40. doi: 10.1016/j.ejca.2018.09.026. Epub 2018 Oct 29.

PMID:
30384014
29.

[Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie].

Guillot B, Charles J, Jeudy G, Cupissol D, Dupuy A, Dutriaux C, Gangloff D, Magne N, Mirabel X, M'Sadek A, Pracht M, Sichel C, Do Outeiro G.

Bull Cancer. 2018 Sep;105(9):780-789. doi: 10.1016/j.bulcan.2018.06.002. Epub 2018 Aug 14. French. No abstract available.

PMID:
30115366
30.

[Haemophagocytic syndrome secondary to Mediterranean spotted fever].

Bertrand AS, Fondain M, Rullier P, Fontaine C, Guillot B.

Ann Dermatol Venereol. 2018 Aug - Sep;145(8-9):516-520. doi: 10.1016/j.annder.2017.10.017. Epub 2018 Jul 10. French.

PMID:
30006110
31.

MAGE-A3 immunotherapeutic as adjuvant therapy for patients with resected, MAGE-A3-positive, stage III melanoma (DERMA): a double-blind, randomised, placebo-controlled, phase 3 trial.

Dreno B, Thompson JF, Smithers BM, Santinami M, Jouary T, Gutzmer R, Levchenko E, Rutkowski P, Grob JJ, Korovin S, Drucis K, Grange F, Machet L, Hersey P, Krajsova I, Testori A, Conry R, Guillot B, Kruit WHJ, Demidov L, Thompson JA, Bondarenko I, Jaroszek J, Puig S, Cinat G, Hauschild A, Goeman JJ, van Houwelingen HC, Ulloa-Montoya F, Callegaro A, Dizier B, Spiessens B, Debois M, Brichard VG, Louahed J, Therasse P, Debruyne C, Kirkwood JM.

Lancet Oncol. 2018 Jul;19(7):916-929. doi: 10.1016/S1470-2045(18)30254-7. Epub 2018 Jun 13.

PMID:
29908991
32.

What is the relationship between the bioaccumulation of chemical contaminants in the variegated scallop Mimachlamys varia and its health status? A study carried out on the French Atlantic coast using the Path ComDim model.

Breitwieser M, Vigneau E, Viricel A, Becquet V, Lacroix C, Erb M, Huet V, Churlaud C, Le Floch S, Guillot B, Graber M, Thomas H.

Sci Total Environ. 2018 Nov 1;640-641:662-670. doi: 10.1016/j.scitotenv.2018.05.317. Epub 2018 Jun 2.

PMID:
29870942
33.

Safety of Oral Propranolol for Infantile Hemangioma.

Droitcourt C, Kerbrat S, Rault C, Botrel MA, Happe A, Garlantezec R, Guillot B, Schleich JM, Oger E, Dupuy A.

Pediatrics. 2018 Jun;141(6). pii: e20173783. doi: 10.1542/peds.2017-3783.

34.

A method to estimate statistical errors of properties derived from charge-density modelling.

Fournier B, Guillot B, Lecomte C, Escudero-Adán EC, Jelsch C.

Acta Crystallogr A Found Adv. 2018 May 1;74(Pt 3):170-183. doi: 10.1107/S2053273318004308. Epub 2018 May 3.

35.

[Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie].

Guillot B, Charles J, Jeudy G, Cupissol D, Dupuy A, Dutriaux C, Gangloff D, Magne N, Mirabel X, M'Sadek A, Pracht M, Sichel C, Do Outeiro G.

Ann Dermatol Venereol. 2018 Jun - Jul;145(6-7):413-422. doi: 10.1016/j.annder.2018.03.165. Epub 2018 Apr 25. French. No abstract available.

PMID:
29703640
36.

[Angiosarcoma of the head and neck treated with bevacizumab and paclitaxel].

Becquart O, Girard C, Lesage C, Guillot B.

Ann Dermatol Venereol. 2018 Jun - Jul;145(6-7):451-453. doi: 10.1016/j.annder.2018.02.008. Epub 2018 Apr 24. French. No abstract available.

PMID:
29703639
37.

Merkel cell carcinoma in France: a registries-based, comprehensive epidemiological survey.

Fondain M, Dereure O, Uhry Z, Guizard AV, Woronoff AS, Colonna M, Molinie F, Bara S, Velten M, Marrer E, Grosclaude P, Lapôtre-Ledoux B, Tretarre B, Guillot B.

J Eur Acad Dermatol Venereol. 2018 Aug;32(8):1292-1296. doi: 10.1111/jdv.14798. Epub 2018 Mar 9.

PMID:
29341266
38.

Distinctive cutaneous and systemic features associated with specific antimyositis antibodies in adults with dermatomyositis: a prospective multicentric study of 117 patients.

Best M, Jachiet M, Molinari N, Manna F, Girard C, Pallure V, Cosnes A, Lipsker D, Hubiche T, Schmutz JL, Le Corre Y, Cordel N, Dandurand M, Dereure O, Guillot B, Du-Thanh A, Bulai Livideanu C, Chasset F, Bouaziz JD, Francès C, Bengoufa D, Vincent T, Bessis D; Study Group of Systemic Diseases in Dermatology (EMSED: Étude des Maladies Systémiques en Dermatologie.

J Eur Acad Dermatol Venereol. 2018 Jul;32(7):1164-1172. doi: 10.1111/jdv.14759. Epub 2018 Jan 31.

PMID:
29237090
39.

PD-1 blockade at the time of tumor escape potentiates the immune-mediated antitumor effects of a melanoma-targeting monoclonal antibody.

They L, Michaud HA, Becquart O, Lafont V, Guillot B, Boissière-Michot F, Jarlier M, Mollevi C, Eliaou JF, Bonnefoy N, Gros L.

Oncoimmunology. 2017 Jul 20;6(10):e1353857. doi: 10.1080/2162402X.2017.1353857. eCollection 2017.

40.

Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.

Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, Ascierto PA, Licitra L, Dutriaux C, Thomas L, Meyer N, Guillot B, Dummer R, Arenberger P, Fife K, Raimundo A, Dika E, Dimier N, Fittipaldo A, Xynos I, Hansson J.

Eur J Cancer. 2017 Nov;86:334-348. doi: 10.1016/j.ejca.2017.08.022. Epub 2017 Nov 5.

41.

Guidelines for the management of acne: recommendations from a French multidisciplinary group.

Le Cleach L, Lebrun-Vignes B, Bachelot A, Beer F, Berger P, Brugère S, Chastaing M, Do-Pham G, Ferry T, Gand-Gavanou J, Guigues B, Join-Lambert O, Henry P, Khallouf R, Lavie E, Maruani A, Romain O, Sassolas B, Tran VT, Guillot B; French Acne Guidelines Working Group and Centre of Evidence of Dermatology.

Br J Dermatol. 2017 Oct;177(4):908-913. doi: 10.1111/bjd.15843. No abstract available.

PMID:
29052890
42.

A family with two cases of melanocytic tumors and fragile X syndrome.

Lesage C, Coupier I, Guillot B.

Melanoma Res. 2017 Dec;27(6):645-648. doi: 10.1097/CMR.0000000000000400.

PMID:
29036014
43.

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.

Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C; GCC (French Group of Skin Cancer).

J Invest Dermatol. 2018 Jan;138(1):58-67. doi: 10.1016/j.jid.2017.07.839. Epub 2017 Aug 24.

44.

A theoretical-electron-density databank using a model of real and virtual spherical atoms.

Nassour A, Domagala S, Guillot B, Leduc T, Lecomte C, Jelsch C.

Acta Crystallogr B Struct Sci Cryst Eng Mater. 2017 Aug 1;73(Pt 4):610-625. doi: 10.1107/S2052520617008204. Epub 2017 Jul 27.

PMID:
28762971
45.

Sporadic Porphyria in a patient with stage II melanoma treated with interferon α.

Reymann V, Girard C, Dereure O, Guillot B, Du Thanh A.

Curr Drug Saf. 2017 May 2. doi: 10.2174/1574886312666170502163628. [Epub ahead of print]

PMID:
28464763
46.

No Viral Transcripts Associated with Folliculotropic Mycosis Fungoides Using a High Throughput Sequencing Approach.

Du-Thanh A, Dereure O, Cheval J, Dumarest M, Al-Shikhley L, Girard C, Guillot B, Eloit M.

Acta Derm Venereol. 2017 Oct 2;97(9):1125-1126. doi: 10.2340/00015555-2686.

47.

Efficacy and Tolerance of Cetuximab Alone or Combined with Chemotherapy in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: An Open Study of 14 Patients.

Dereure O, Missan H, Girard C, Costes V, Guillot B.

Dermatology. 2016;232(6):721-730. doi: 10.1159/000461578. Epub 2017 Apr 7.

48.

Macrophage activation syndrome: A new complication of checkpoint inhibitors.

Malissen N, Lacotte J, Du-Thanh A, Gaudy-Marqueste C, Guillot B, Grob JJ.

Eur J Cancer. 2017 May;77:88-89. doi: 10.1016/j.ejca.2017.02.016. Epub 2017 Mar 31. No abstract available.

PMID:
28365531
49.

Directional O...F halogen bonds.

Jelsch C, Guillot B.

Acta Crystallogr B Struct Sci Cryst Eng Mater. 2017 Apr 1;73(Pt 2):136-137. doi: 10.1107/S205252061700467X. Epub 2017 Mar 29. No abstract available.

PMID:
28362274
50.

Is photodynamic therapy a relevant therapeutic option in refractory benign familial pemphigus (Hailey-Hailey disease)? A series of eight patients.

Alsahli M, Debu A, Girard C, Bessis D, Du Thanh A, Guillot B, Dereure O.

J Dermatolog Treat. 2017 Nov;28(7):678-682. doi: 10.1080/09546634.2017.1308461. Epub 2017 Apr 2.

PMID:
28301978

Supplemental Content

Loading ...
Support Center